rs1571583 — GLIS3 GLIS3 Beta Cell Development Variant

Intronic GLIS3 variant in which the rare A allele modestly elevates TSH, reflecting reduced thyroid transcriptional activity; the same gene drives pancreatic beta cell development, linking thyroid-axis regulation to metabolic energy balance

See your personal result for GLIS3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GLIS3: The Transcription Factor Linking Thyroid and Beta Cell Development

Most genes do one job. GLIS3 (GLIS family zinc finger 3) does two: it is a master transcription factor required for the development of both thyroid follicular cells and pancreatic beta cells. Rare loss-of-function mutations in GLIS3 cause a syndrome of neonatal diabetes combined with congenital hypothyroidism — a clinical double-hit that reveals just how foundational this single gene is to two of the body's most metabolically critical tissues. The common rs1571583 variant is a far subtler version of the same signal: a population-frequency intronic variant in which one allele nudges thyroid stimulating hormone upward, shifting the thyroid setpoint in a direction associated with lower metabolic rate, greater fat accumulation tendency, and modestly elevated type 2 diabetes risk.

The Mechanism

rs1571583 lies within an intron of GLIS3 on chromosome 9p24.2. It does not change the protein sequence but is believed to influence GLIS3 expression levels in a tissue-specific manner, consistent with the regulatory architecture of its chromosomal neighbourhood. GLIS3 protein controls transcription of the thyroid-specific genes needed for thyroid follicle formation and thyroid hormone synthesis — including thyroglobulin (TG) and sodium/iodide symporter (SLC5A5/NIS). Even subtle reductions in GLIS3 activity in the thyroid translate into less efficient thyroid hormone output, prompting the pituitary to release more [TSH (thyroid stimulating hormone) | TSH is secreted by the anterior pituitary in response to low circulating T3/T4; it stimulates the thyroid gland to produce and release thyroid hormones, completing a classic negative-feedback endocrine loop] to drive compensatory output. The result is a higher TSH setpoint without overt hypothyroidism — but measurably less metabolic efficiency.

In the pancreas, GLIS3 activates neurogenin 3 (NGN3) in cooperation with HNF6 and FOXA2 to drive fetal islet differentiation, and it maintains adult beta cell function by co-operating with PDX1, MAFA, and NEUROD1 on the insulin gene promoter. GLIS3 is also required for compensatory beta cell mass expansion when insulin resistance develops. Variants that mildly reduce GLIS3 expression therefore create a dual vulnerability: a slightly less responsive thyroid axis and a reduced capacity for beta cell compensation under metabolic stress.

The Evidence

The foundational population study was a meta-analysis of thyroid-related traits by Porcu et al.11 meta-analysis of thyroid-related traits by Porcu et al.
Porcu E et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet 2013 in 26,420 euthyroid subjects. GLIS3 was identified as one of 15 novel genome-wide significant TSH loci; the A allele at rs1571583 was associated with higher TSH (beta +0.057 per allele copy, p=2.55×10⁻⁸). The effect is modest per allele, but measurable — two A alleles shift the TSH distribution upward by roughly 0.11 units, a difference detectable within the normal reference range. The study also found that the GLIS3 locus, along with four other loci, showed gender-specific differences in its effect on thyroid function, with the TSH-raising effect appearing somewhat stronger in males (beta +0.074, p=1×10⁻⁶ in male-stratified analysis).

A 2023 study by Mulder et al.22 Mulder et al.
Mulder TA et al. Genetic determinants of thyroid function in children. Eur J Endocrinol 2023 found that among 60 thyroid-function SNPs, the GLIS3 locus showed notably larger effect sizes in children compared to adults — consistent with GLIS3's well-documented developmental role in thyroid differentiation during fetal and early postnatal life.

The diabetes connection is supported by a body of work on GLIS3's functional requirement in beta cells. Wen and Yang's review33 Wen and Yang's review
Wen X, Yang Y. Emerging roles of GLIS3 in neonatal diabetes, type 1 and type 2 diabetes. J Mol Endocrinol 2017 summarises that GWAS data show GLIS3 variants are associated with both T1D and T2D, and that GLIS3 is required for compensatory beta cell mass expansion under insulin resistance — meaning individuals with reduced GLIS3 activity may have a reduced buffer capacity when metabolic demand rises. A 2024 study in Diabetologia44 2024 study in Diabetologia
Meulebrouck S et al. Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk. Diabetologia 2024 found that rare pathogenic GLIS3 variants confer OR 2.1 [95% CI 1.4-2.9] for T2D — a strong functional validation that GLIS3 loss-of-function is causally linked to diabetes.

Practical Actions

For A-allele carriers, the primary actionable implication is the elevated TSH tendency. High-normal TSH — even within the reference range — is associated with slower metabolic rate, a tendency toward weight gain, impaired lipid clearance, and reduced thermogenesis. Iodine and selenium are the two dietary micronutrients with the most evidence-backed roles in thyroid hormone synthesis and peripheral conversion: iodine as the essential substrate for T3/T4 biosynthesis, selenium as a cofactor for the deiodinase enzymes that convert T4 into the active T3 form. A-allele carriers who already have high-normal TSH should ensure adequate — but not excessive — dietary iodine and confirm their selenium status, since selenium deficiency compounds thyroid underactivity.

Periodic TSH monitoring is warranted because the A allele shifts the setpoint upward; over time, what starts as high-normal TSH can drift into subclinical hypothyroidism, particularly with age or pregnancy. Annual TSH testing identifies this drift before symptoms (fatigue, cold intolerance, weight gain) develop.

Interactions

GLIS3 sits at the intersection of two major endocrine systems. Within the thyroid axis, rs903814 (another GLIS3-region variant) has been independently associated with TSH in some populations, and the two may jointly influence the GLIS3 expression setpoint. Within the pancreatic beta cell axis, GLIS3 function intersects with TCF7L2 (rs7903146) — the strongest common T2D locus — since both regulate beta cell mass and insulin gene transcription. Carriers of both a reduced-function GLIS3 allele and a TCF7L2 risk allele may face compounded reduction in beta cell reserve capacity, though direct published evidence for this specific combination is not yet available.

The related GLIS3 variants rs7034200 and rs7041847 have been associated with fasting glucose and T2D risk in East Asian GWAS studies and likely tag the same functional haplotype through their LD with rs1571583.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal TSH Setpoint Normal

Common genotype; normal GLIS3-mediated thyroid function setpoint

You have two copies of the common G allele at rs1571583. Your GLIS3 gene expression in thyroid follicular cells is at the typical population level, and your pituitary TSH setpoint reflects normal thyroid hormone feedback. About 58% of people of European descent share this genotype. No specific thyroid or metabolic action is indicated by this variant alone.

AG Mildly Elevated TSH Tendency Intermediate

One copy of the A allele; modest upward shift in TSH setpoint

The TSH effect size of +0.057 per A allele (Porcu et al. 2013, 26,420 subjects) is small in absolute terms but represents a real upward shift of the setpoint. For heterozygotes, this means TSH readings in the 3-4 mIU/L range — still "normal" by most laboratory cutoffs — are more common than in GG carriers. Several large studies have shown that TSH in the upper half of the reference range is associated with higher body weight, greater visceral fat, worse lipid profiles, and marginally reduced insulin sensitivity compared to TSH in the lower half.

GLIS3 also regulates pancreatic beta cell mass expansion under metabolic stress. Heterozygous A carriers have modestly reduced GLIS3 activity, which may slightly reduce their beta cell compensation reserve — relevant if insulin resistance develops over time.

AA Higher TSH Setpoint High Risk

Two copies of the A allele; meaningful upward shift in TSH setpoint with associated metabolic implications

Homozygous AA carriers sit at the high-TSH tail of the GLIS3 distribution. The +0.114 TSH unit shift (two copies × beta 0.057) is detectable within the euthyroid range but places most carriers in the 3-4.5 mIU/L zone where metabolic consequences of thyroid underperformance accumulate subtly over years: lower resting metabolic rate (thyroid hormones drive ~30% of basal metabolic rate via mitochondrial uncoupling and Na/K-ATPase activity), slightly elevated LDL cholesterol, reduced thermogenesis, and greater fat accumulation in the context of excess caloric intake.

The 2024 Diabetologia study (Meulebrouck et al.) confirmed that loss-of-function GLIS3 variants — including common ones — are associated with OR 2.1 for T2D, and that all GLIS3-related T2D patients in that cohort were sensitive to sulfonylureas. This suggests that if glucose dysregulation develops in AA carriers, the beta cell deficit is at least partially rescued by sulfonylurea therapy — a clinically actionable pharmacogenomic note.

GLIS3's sex-specific effects are worth noting: the Porcu 2013 meta-analysis found stronger TSH effects in males (beta +0.074 in males vs. smaller in females) for the GLIS3 locus, suggesting male AA carriers may experience a somewhat larger functional shift in thyroid axis than females.